Table3A.
Predictors of positive antibody response after two doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases treated with rituximab- in relation to time between the last rituximab course and vaccination.
| B | p-value | OR | 95 % CI | |
|---|---|---|---|---|
| Time between last rituximab treatment and vaccination (months) | 0.24 | 0.003 | 1.28 | 1.09–1.50 |
| Age at vaccination (years) | −0.04 | 0.023 | 0.96 | 0.93–0.99 |
| Sex (female/male) | 0.63 | 0.159 | 1.87 | 0.78–4.47 |
| Methotrexate at vaccination (yes/no)* | −0.69 | 0.143 | 0.50 | 0.20–1.26 |
| Rituximab dos (1000 mg vs 500 mg) | −0.42 | 0.337 | 0.65 | 0.28–1.56 |
| Smoking (never/ever) | 0.01 | 0.823 | 1.10 | 0.47–2.57 |
| Diagnosis at vaccination (systemic vasculitis vs others) | −0.22 | 0.659 | 0.81 | 0.31–2.10 |
| Comorbidity (yes/no) | −0.68 | 0.347 | 0.50 | 0.12–2.10 |
Binary logistic regression analysis adjusted for age, sex, methotrexate, prednisolone dose, smoking status, diagnosis (systemic vasculitis), rituximab dose, comorbidity at vaccination.
*
Concomitant csDMARD (conventional synthetic anti-rheumatic drugs) and methotrexate were tested in two different models.